HowardFillitMD

Founding Executive Director and Chief Science Officer Alzheimer's Drug Discovery Foundation

Dr. Fillit is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Alzheimer's Drug Discovery Foundation, 57 West 57 Street
904
New York, NY 10019
Phone+1 212-901-8000

New York Presbyterian Hospital (Cornell Campus)Fellowship, Nephrology, 1979 - 1980
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1974 - 1976
SUNY Upstate Medical UniversityClass of 1974

PubMed

Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery founda...
Jeffrey Cummings, Michael Gold, Mark Mintun, Michael Irizarry, Andrew von Eschenbach
The Journal of Prevention of Alzheimer's Disease. 2025-01-01
3 citations
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
Dawn C Matthews, Jefferson W Kinney, Aaron Ritter, Randolph D Andrews, Erin N Toledano Strom
Alzheimer's & Dementia. 2024-07-09
1 citations
Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia.
Natalia Olchanski, Yingying Zhu, Lichen Liang, Joshua T Cohen, Jessica D Faul
Journal of the American Geriatrics Society. 2024-04-01

We Finally Have New Alzheimer’s Drugs. How Do We Decide Who Gets Them?July 2023
It’s Time to Move Past Aduhelm and Focus on a Broader Alzheimer’s Drug PipelineJune 2022
We Need New Biomarkers for Alzheimer's DiseaseSeptember 2018
In the Search for Alzheimer’s Drugs, Researchers Must Look Beyond Beta AmyloidNovember 2017
Join now to see all

Dr. Howard Fillit: The Future of Precision Medicine in Alzheimer’s Disease TreatmentDecember 2nd, 2024
DATAcc by DiMe Launches Core Digital Measures for Alzheimer’s Disease and Related DementiasNovember 14th, 2024
Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-Month Phase 2 Study, Meeting Primary and Key Secondary EndpointsOctober 31st, 2024
Join now to see all

Drug Discovery For NeurodegenerationNational Institute On Aging2007–2011
Drug Discovery For NeurodegenerationNational Institute On Aging2010
Immunobiology Of Autoimmunity To Heparan SulfateNational Institute Of Allergy And Infectious Diseases1994–1997
Autoimmunity To Proteoglycans In Autoimmune DiseaseNational Institute Of Allergy And Infectious Diseases1991–1993
Pilot Study -- Heparan Sulfate Proteoglycans In Alzheimer'S DiseaseNational Institute On Aging1989–1993
Specificity Of Human Autoantibodies To ProteoglycansNational Institute Of Allergy And Infectious Diseases1990–1992
Neuroendocrine And Neuroimmune Studies Of Alzheimers Disease And AgingNational Center For Research Resources1987–1988
Immunological Probes In Alzheimer'S DiseaseNational Center For Research Resources1985–1988
Immunological Studies In GlomerulonephritisNational Center For Research Resources1985–1986